Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $23

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $25 to $23.